Genmab A/S GMAB
| Analyste |
Entreprise |
Prix lors de l'analyse |
Prix cible |
Gain potentiel |
Date de publication |
| Asthika Goonewardene |
Truist Financial |
33.56 $ |
49 $ |
15.44 % |
06/10/2025 |
| Jonathan Chang |
Leerink Partners |
29.1566 $ |
34 $ |
4.84 % |
29/09/2025 |
| Michael Schmidt |
Guggenheim |
28.6 $ |
43 $ |
14.40 % |
23/09/2025 |
| Asthika Goonewardene |
Truist Financial |
20.26 $ |
45 $ |
24.74 % |
11/03/2025 |
| Vikram Purohit |
Morgan Stanley |
27.41 $ |
31 $ |
3.59 % |
04/09/2024 |
| Etzer Darout |
BMO Capital |
27.07 $ |
46 $ |
18.93 % |
09/08/2024 |
| Kaveri Pohlman |
BTIG |
25.67 $ |
47 $ |
21.33 % |
27/06/2024 |
| Raghuram Selvaraju |
H.C. Wainwright |
25.71 $ |
50 $ |
24.29 % |
27/06/2024 |
| Asthika Goonewardene |
Truist Financial |
28.83 $ |
53 $ |
24.17 % |
04/06/2024 |
| Etzer Darout |
BMO Capital |
29.16 $ |
48 $ |
18.84 % |
23/02/2024 |
| Matthew Harrison |
Morgan Stanley |
44.83 $ |
34 $ |
-10.83 % |
28/11/2022 |